PDF herunterladen
Thromb Haemost 1990; 64(01): 061-068
DOI: 10.1055/s-0038-1647254
Original Article
Schattauer GmbH Stuttgart

Effect of Fibrin-Like Stimulators on the Activation of Plasminogen by Tissue-Type Plasminogen Activator (t-PA) - Studies with Active Site Mutagenized Plasminogen and Plasmin Resistant t-PA[*]

H R Lijnen
The Centerfor Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium
,
B Van Hoet
The Centerfor Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium
,
F De Cock
The Centerfor Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium
,
D Collen
The Centerfor Thrombosis and Vascular Research, University of Leuven, Leuven, Belgium
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 10. Januar 1990

Accepted after revision 27. April 1990

Publikationsdatum:
25. Juli 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

The activation of plasminogen by t-PA was measured in the presence and absence of fibrin stimulation, using natural human plasminogen (nPlg) and rPlg-Ala740, a recombinant plasminogen with the active site Ser740 mutagenaed to Ala. Recombinant wild type t-PA (rt-PA) was used as well as rt-PA -Glul275, a recombinant single chain t-PA in which the Arg of the plasmin sensitiv e Arg275- Ile276 peptide bond was substituted with Glu. Conversion of 125I-labeled single chain plasminogen to two-chain plasmin by wild-type or mutant t-PA, was quantitated by SDS gel electrophoresis and radioisotope counting of gel slices, and expressed as initial activation rates (v0 in pM s−1) per 1 μM enzyme. In the absence of fibrin stimulation, the vs for the activation of nPlg and rPlg-Ala740 with the single chain forms of both t-PAs were comparable (0.6 to 2.7 pM s−1) but were lower than with the corresponding two-chain forms (5.3 to 23 pM s−1). In the presence of 1 μM soluble fibrin monomer (desAAfibrin), the v0 for nPlg and rPlg-Ala740 by single chain rt-PA was also comparable (24 and, 33 pM s-1 respectively), whereas with 1 pM CNBr-digested fibrinogen, the vs for nPlg with single chain rt-PA was about 20-fold higher than that of rPlg-Ala740 (135 and 7.5 pM s−1 respectively). In contrast, the vs for nPlg and rPlg-Ala740 by single chain rt-PA- G1u275, two-chain rt-PA-G1u275 or two-chain rt-PA were comparable in the presence of either desAAfibrin or CNBr-digested fibrinogen.

These findings confirm and establish: 1) that single chain t-PA is an active enzyme both in the presence and absence of fibrin stimulator; 2) that, in a system devoid of plasmin activity (rPlg- Ala740), the two-chain form of t-PA is about L5 times more active than the single chain form in the absence of fibrin but equipotent in the presence of desAAfibrin; and 3) that the mechanism of stimulation of plasminogen activation with single chain t-PA by CNBr-digested fibrinogen is different from that by soluble fibrin.

Dedicated to Professor M. Verstraete on the occasion of his 65th birthday


 

  • References

  • 1 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
    PubMedGoogle Scholar
  • 2 Wallen P, Wiman B. Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen. Biochim Biophys Acta 1972; 257: 122-134
    PubMedGoogle Scholar
  • 3 Sottrup-Jensen L, Petersen TE, Magnusson S. Atlas of Protein Sequence and Structure. Vol 5, Suppl 3 Dayhoff MO. (ed) National Biomedical Research Foundation; Washington DC: 1978: 91
  • 4 Robbins KC, Summaria L, Hsieh B, Shah RJ. The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 1967; 242: 2333-2342
    PubMedGoogle Scholar
  • 5 Holvoet P, Lijnen HR, Collen D. A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo. J Biol Chem 1985; 260: 12106-12111
    PubMedGoogle Scholar
  • 6 Summaria L, Arzadon L, Bemabe P, Robbins KC. The activation of plasminogen to plasmin by urokinase in the presence of the plasmin inhibitor trasylol. The preparation of plasmin with the same NH2-terminal heavy (A) chain sequence as the parent zymogen. J Biol Chem 1975; 250: 3988-3995
    PubMedGoogle Scholar
  • 7 Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983; 301: 214-221
    PubMedGoogle Scholar
  • 8 Camiolo SM, Thorsen S, Astrup T. Fibrinogenolysis and fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc Soc Exp Biol Med 1971; 138: 277-280
    CrossrefPubMedGoogle Scholar
  • 9 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-2919
    PubMedGoogle Scholar
  • 10 Rijken DC, Hoylaerts M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982; 257: 2920-2925
    PubMedGoogle Scholar
  • 11 Higgins DL, Vehar GA. Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin. Biochemistry 1987; 26: 7786-7791
    CrossrefPubMedGoogle Scholar
  • 12 Husain SS, Hasan A AK, Budzynski AZ. Differences between binding of one-chain and two-chain tissue plasminogen activators to non-cross-linked and cross-linked fibrin clots. Blood 1989; 74: 999-1006
    PubMedGoogle Scholar
  • 13 Suenson E, Luetzen O, Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feed-back mechanism in fibrinolysis. Eur J Biochem 1984; 140: 513-522
    CrossrefPubMedGoogle Scholar
  • 14 Tate KM, Higgins DL, Holmes WE, Winkler ME, Heyneker HL, Vehar GA. Functional role of proteolytic cleavage at Arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. Biochemistry 1987; 26: 338-343
    CrossrefPubMedGoogle Scholar
  • 15 Busby SJ, Rao D, Heipel M, Markson M, Loubin P, Mulvihill E. Expression of human plasminogen in baby hamster kidney cells. Fibrinolysis 1988; 2 (Suppl. 01) 64 (abstract 147)
    PubMedGoogle Scholar
  • 16 Verheijen JH, Mullaart E, Chang G TG, Kluft C, Wijngaards F. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-269
    PubMedGoogle Scholar
  • 17 Zamarron C, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by natural and recombinant tissue-type plasminogen activator. J Biol Chem 1984; 259: 2080-2083
    PubMedGoogle Scholar
  • 18 Lijnen HR, Uytterhoeven M, Collen D. Inhibition of trypsin-like serine proteinases by tripeptide arginyl and lysyl chloromethyl-ketones. Thromb Res 1984; 34: 431-437
    CrossrefPubMedGoogle Scholar
  • 19 Collen D, Lijnen HR, De Cock F, Durieux JP, Loffet A. Kinetic properties of tripeptide lysyl chloromethyl ketone and lysyl p-nitroanilide derivatives towards trypsin-like serine proteinases. Biochim Biophys Acta 1980; 165: 158-166
    PubMedGoogle Scholar
  • 20 Shapiro RA, Scherer NM, Habecker BA, Subers EM, Nathanson NM. Isolation, sequence and functional expression of the mouse Ml muscarinic acetylcholine receptor gene. J Biol Chem 1988; 263: 18397-18403
    PubMedGoogle Scholar
  • 21 Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158. J Biol Chem 1987; 262: 5682-5689
    PubMedGoogle Scholar
  • 22 Deutsch DG, Mertz ET. Plasminogen: purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
    CrossrefPubMedGoogle Scholar
  • 23 Holmes WE, Lijnen HR, Collen D. Characterization of recombinant human α2-antiplasmin and of mutants obtained by site-directed mutagenesis of the reactive site. Biochemistry 1987; 26: 5133-5140
    CrossrefPubMedGoogle Scholar
  • 24 Fraker PJ, Speck Jr JC. Protein and cell membrane iodinations with a sparingly soluble chloroamide 1,3,4,6-tetrachloro-3a,6a-diphenylgly-coluril. Biochem Biophys Res Commun 1978; 80: 849-857
    CrossrefPubMedGoogle Scholar
  • 25 Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator. J Biol Chem 1987; 262: 10855-10862
    PubMedGoogle Scholar
  • 26 Holvoet P, Lijnen HR, Collen D. Characterization of functional domains in human tissue-type plasminogen activator with the use of monoclonal antibodies. Eur J Biochem 1986; 158: 173-177
    CrossrefPubMedGoogle Scholar
  • 27 Wallen P, Wiman B. Characterization of human plasminogen. I. On the relationship between different molecular forms of plasminogen demonstrated in plasma and found in purified preparations. Biochim Biophys Acta 1970; 221: 20-30
    PubMedGoogle Scholar
  • 28 Holvoet P, Cleemput H, Collen D. Assay of human tissue-type plasminogen activator (t-PA) with an enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 1985; 54: 684-687
    PubMedGoogle Scholar
  • 29 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254
    CrossrefPubMedGoogle Scholar
  • 30 Blomback B, Blomback M. Purification of human and bovine fibrinogen. Arkiv Kemi 1956; 10: 415-443
    PubMedGoogle Scholar
  • 31 Astrup T, Muellertz S. Fibrin plate method for estimating fibrinolytic activity. Arch Biochem Biophys 1952; 40: 346-351
    CrossrefPubMedGoogle Scholar
  • 32 Gaffney PJ, Curtis AD. A collaborative study to establish the 2nd international standard for tissue plasminogen activator (t-PA). Thromb Haemostas 1987; 58: 1085-1087
    PubMedGoogle Scholar
  • 33 Lijnen HR, Van Hoef B, De Cock F, Collen D. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro. Blood 1989; 73: 1864-1872
    PubMedGoogle Scholar
  • 34 Ranby M, Bergsdorf N, Norrman B, Suenson E, Wallen P. Tissue plasminogen activator kinetics. In: Progress in Fibrinolysis, Vol 6 Davidson JF, Bachman F, Wallen P, Bouvier CA, Kruithof EK O. (eds). Churchill Livingstone, Edinburgh: 1983: 182-184
  • 35 Johannessen M, Nielsen F, Petersen LC. Plasmin-catalysed cleavage of single chain tissue-type plasminogen activator in fibrin clots. Fibrinolysis 1989; 3: 215-220
    PubMedGoogle Scholar
  • 36 Ranby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982; 704: 461-469
    CrossrefPubMedGoogle Scholar
  • 37 Nieuwenhuizen W, Voskuilen M, Vermond A, Hoegee-de Nobel B, Traas DW. The influence of fibrin(ogen) fragments on the kinetic parameters of the tissue-type plasminogen-activator-mediated activation of different forms of plasminogen. Eur J Biochem 1988; 174: 163-169
    CrossrefPubMedGoogle Scholar
  • 38 Boose JA, Kuismanen E, Gerard R, Sambrook J, Gething MJ. The single-chain form of tissue-type plasminogen activator has catalytic activity: studies with a mutant enzyme that lacks the cleavage site. Biochemistry 1989; 28: 635-643
    CrossrefPubMedGoogle Scholar
  • 39 Andreasen PA, Nielsen LS, Grondahl-Hansen J, Skriver L, Zeuthen J, Stephens RW, Dano K. Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody. EMBO J 1984; 3: 51-56
    PubMedGoogle Scholar
  • 40 Petersen LC, Boel E, Johannessen M, Foster D. Possible involvement of a lysine residue in establishing the charge-relay system responsible for one-chain t-PA activity. Thromb Haemostas 1989; 62: 322 (Abstr)
    PubMedGoogle Scholar